Compare Alcon AG (ALC) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Teladoc Health Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Teladoc Health Inc trades at $9.15 (market cap $1.72B). The key difference: Alcon AG is far larger — about 19× Teladoc Health Inc's market cap, and Alcon AG pays a 0.54% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| ALC | TDOC | |
|---|---|---|
Market Cap | $32.69B | $1.72B |
Sector | Health | Health |
52-Week High | $92.22 | $9.52 |
52-Week Low | $62.02 | $4.47 |
Enterprise Value | $36.28B | $2.01B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Teladoc Health (TDOC) trades at $9.52, up 3.48% today, with technical indicators showing bullish momentum despite overbought RSI readings. The company reported Q1 2026 earnings that missed expectations, but revenue remains stable at $2.53 billion for 2025. Recent news highlights expansion through Walmart's platform and ongoing cost-cutting efforts, though BetterHelp segment weakness persists. Analyst consensus is mixed with 33% buy ratings but a price target below current levels at $7.83.
TDOC's recovery story faces headwinds from persistent net losses and negative cash flow, but low P/S ratio of 0.66 offers valuation appeal. Key risks include competitive pressure and execution challenges, while institutional sentiment remains cautious with no sell ratings. The stock's near-term direction hinges on Q2 earnings results and progress toward profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
